In a new deal, #AstraZeneca has licensed a promising COPD therapy from #SinoPharmaceuticals, securing the rights to develop, manufacture and commercialise TQC3721. Discover more: www.emjreviews.com/emj-gold/new... #COPD

An #Ebola treatment trial has kicked off in the #DRC, testing two drugs separately and together to see if they are effective against the #Bundibugyo strain. Discover more: www.emjreviews.com/emj-gold/new... #GlobalHealth

What shaped pharma in June? This roundup covers the biggest stories in healthcare, from a landmark new #NHS treatment for #OvarianCancer to #Ebola vaccine investment, #Biotech deals and pharma's initiatives at the #FIFAWorldCup2026. Read now: www.emjreviews.com/emj-gold/new... #Pharma

Who picks up the bill for better medicines? A new analysis suggests the UK-US pharmaceutical trade deal could require up to £45bn in additional NHS medicines spending by 2036. Read more: www.emjreviews.com/emj-gold/new... #NHS #HealthcarePolicy #Pharma

Older adults in the US with obesity can now access Novo Nordisk’s injection and pill through a new access pathway, with a monthly copayment of $50. Find out more: www.emjreviews.com/emj-gold/new... #Obesity

There's more to discover from our time at #EHA2026. We sat down with Ester in ’t Groen, TA Head, Haematology, J&J Innovative Medicine EMEA, to discuss the rapid evolution of #multiplemyeloma treatment and the innovations bringing new hope to patients. Watch now: www.emjreviews.com/emj-gold/art...

The #MHRA is cracking down on the promotion of weight-loss medicines. The UK regulator has warned businesses against advertising newly licensed and unlicensed weight-management medicines, reinforcing existing rules. Learn more: www.emjreviews.com/emj-gold/new... #WeightLoss

What will it take to accelerate access to a vaccine for Bundibugyo #Ebola? #UNICEF and #Gavi have launched a new initiative to help speed up manufacturing readiness for a Bundibugyo Ebolavirus vaccine as outbreaks continue in the DRC and Uganda. 🔗: www.emjreviews.com/emj-gold/new...

Couldn't make it to EHA 2026? We've got you covered. In Stockholm, we sat down with Aliya Omer, Global Head, Haematology Franchise, AstraZeneca, to discuss the innovations shaping the future of haematological cancer care. Watch now: www.emjreviews.com/emj-gold/art... #Haematology

As H5N1 reaches South Australia for the first time, the government is investing more than $113m to strengthen surveillance, biosecurity and pandemic readiness. 🔗: www.emjreviews.com/emj-gold/new... #BirdFlu

Can Europe afford delays in access to innovative medicines? New data from suggests faster access to new therapies could improve patient outcomes, reduce hospital stays and deliver significant economic benefits. Find out more: www.emjreviews.com/emj-gold/new... #AccesstoMedicine

A new epilepsy diagnosis is made every minute in Europe. In this episode, Rafal Kaminski, Chief Scientific Officer, Angelini Pharma, explores how scientific innovation is reshaping brain health, with a focus on epilepsy. Listen now: www.emjreviews.com/emj-gold/pod... #BrainHealth

Could an oral GLP-1 broaden access to treatment? The MHRA has approved Novo Nordisk's semaglutide tablets in the UK, providing a new option for patients who are hesitant about injectable therapies. Learn more: www.emjreviews.com/emj-gold/new... #Obesity

Tony Wood, Chief Scientific Officer, GSK, said: “With antibiotic resistance continuing to rise, patients and healthcare professionals need new treatment options." The antibiotic should be available in the US by the end of 2026. Discover more: www.emjreviews.com/emj-gold/new... #UTIs

As momentum returns to the biotech market, #Biogen has become the latest big pharmaceutical company to snap up a promising biotech, buying #RayThera for up to $1bn. Read the full story: www.emjreviews.com/emj-gold/new... #Biotech #Pharma

As the event gets underway, #Genentech, #Amgen, #Sanofi and #BristolMyersSquibb are supporting initiatives in cities where they have a significant presence, including: - New York and New Jersey - Los Angeles - Boston - San Francisco. 🔗: www.emjreviews.com/emj-gold/new... #FIFAWorldCup #Pharma

Pharmaceutical supply chains are facing growing pressure from geopolitical instability, cyberattacks, manufacturing constraints and counterfeit medicines, according to a new Moody's report. Read the full story here: www.emjreviews.com/emj-gold/new... #Pharma #SupplyChain

Thousands of young people in England will be offered a two-dose MenB vaccine ahead of the 2026 academic year following a rise in meningococcal B cases and recent outbreaks. Read the full story: hubs.la/Q04lc3Kb0 #Vaccines #Meningitis

The FDA is tightening enforcement on compounded GLP-1 drugs after linking them to 1,150+ adverse events, 100 hospitalisations and at least 10 deaths. Read more: www.emjreviews.com/emj-gold/new... #FDA #obesity

GSK is to acquire Nuvalent: its biggest acquisition in more than a decade. Luke Miels, CEO, GSK, described the deal as creating “a platform for rapid expansion in lung cancer”, as the company seeks rebuild its oncology business. Read now: www.emjreviews.com/emj-gold/new... #Oncology

💥New interview live now💥 Hear from Dr Siddharth Jain, Head, Global Medical Unit for Growth & Launch Brands for Rare Diseases, Takeda. He explores: - The future of medical affairs - What could transform rare disease care - And more! www.emjreviews.com/emj-gold/art... #RareDiseases #MedicalAffairs

What makes an HCP open an email? In our latest white paper, we asked HCPs exactly that. Their top priorities were: 📩 Clinical relevance 🤝 A trusted sender ✍️ A personalised subject line 📊 New evidence Discover more findings 👇 www.emjreviews.com/emj-gold/inf...

Following CEPI's pledge last week, Gavi's First Response Fund will make up to $40m available to vaccine developers working on solutions to combat the current active strain of Ebola. Read the full story below 👇 www.emjreviews.com/emj-gold/new...

The obesity market is unforgiving, with #Boehringer's phase 3 results causing a market spook despite the trial meeting its primary endpoints. However, the picture was more rosy in liver disease. Learn more: www.emjreviews.com/emj-gold/new... #Obesity

After a tumultuous month at HQ, the #FDA has released new guidance that aims to speed up R&D of genome editing therapies. Learn more: www.emjreviews.com/emj-gold/new...

📣 Around 400 women a year set to benefit from new #ovariancancer treatment. The NHS has approved AbbVie’s mirvetuximab soravtansine, offering new hope for patients whose disease has stopped responding to standard chemotherapy. Discover more: www.emjreviews.com/emj-gold/new...

May in pharma, explained 👇 From a potential breakthrough in pancreatic cancer to fresh Ebola concerns and more FDA leadership turmoil, discover the stories that shaped the last month in the pharma industry. Read the roundup: www.emjreviews.com/emj-gold/new... #PharmaNews #Oncology #FDA

The study, conducted by Cumberland Pharmaceuticals and Vanderbilt Health, evaluated solid tumours considered at high risk of early metastatic recurrence, including breast, lung, pancreatic, soft tissue, bladder and renal cancers. Discover more: www.emjreviews.com/emj-gold/new... #Oncology

“With Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease,” said Dr Richard Hatchett, CEO, CEPI. This urgency is driving the decision to advance three vaccines in parallel. Read more: hubs.la/Q04jJb3S0 #Ebola

More than 100 emails land in the average HCP inbox each day. In a new white paper, we surveyed the audience to provide teams serious about improving their email strategy with a clearer picture of what truly works. 🔗 hubs.la/Q04jbt-x0 #PharmaMarketing #MedicalAffairs

The US drugmaker is set to acquire #Curevo, #LimmaTechBiologics and #VaccineCompany, which are testing candidates for shingles, bacterial infections and the Epstein-Barr virus, respectively. Read more: www.emjreviews.com/emj-gold/new... #EliLilly #vaccines #aquisition

🚨 BREAKING: Europe's medicines watchdog has recommended Novo Nordisk's #semaglutide pill for approval, which would make it the first oral weight-loss drug on the continent. Get the full details: www.emjreviews.com/emj-gold/new... #Obesity #Pharma #GLP1

The use of AI in medical imaging is on the rise – the market could grow by 30% over the next five years – but what's the main driver behind the uptick? Find out: www.emjreviews.com/emj-gold/new... #ArtificialIntelligence #HealthTech #MedicalImaging #Radiology

“The science is moving faster than the regulatory system around it.” To celebrate #WorldClinicalTrialsDay, the team spoke to Muriel O’Byrne, Regeneron, about the opportunities and challenges shaping the future of clinical trials today. Read now: www.emjreviews.com/emj-gold/art...

A new study by Prof Majid Ezzati of @imperialcollegeldn.bsky.social has examined global obesity rates, uncovering a black mark on the otherwise rosy picture of improved outcomes. Read the story: www.emjreviews.com/emj-gold/new...

Following the latest #Ebolavirus outbreak in the Democratic Republic of Congo, attention is turning to antiviral candidates such as #NanoViricides’ NV-387 – a stable oral antiviral in that may also be available as a gummy. Learn more: www.emjreviews.com/emj-gold/new...

Has the UK learned from past mistakes in pandemic policy? The nation has imported the experimental antiviral drug favipiravir as a precaution against any further cases of the deadly #Andeshantavirus. Read now: www.emjreviews.com/emj-gold/new...

After daraxonrasib's phase 3 trial results were released, there has reportedly been “a deluge of patient requests” for the therapy. Learn more: hubs.ly/Q04gCHKC0 #PancreaticCancer #daraxonrasib

Couldn't make it to #WIREDHealth2026? We've got the pharma highlights. The team was there to find out how healthcare leaders, NHS figures and tech executives think AI, data and new technologies could reshape medicine. Read the roundup: www.emjreviews.com/emj-gold/art...

Update: GSK has partnered with Sino Biopharmaceutical subsidiary CTTQ to commercialise investigational hepatitis B therapy bepirovirsen in China. Read more: www.emjreviews.com/emj-gold/new... #HepatitisB #ChinaHealthcare

April in pharma, explained 👇 In our latest news roundup, explore: - A major month for the obesity market - The impact of war on clinical trials - The rise of tech giants in AI-driven R&D. Read it now: www.emjreviews.com/emj-gold/new...

Major M&A move: #Angelini Pharma is buying #Catalyst Pharmaceuticals, Inc. for $4.1bn in its biggest deal to date and its first significant move into the US market. Read the story: hubs.la/Q04fPHZP0 #neurology #brainhealth

#Novartis has been selected as an official partner of the 2029 #SpecialOlympics World Winter Games, which bring together athletes with cognitive disabilities to compete in elite winter sports such as skiing, figure skating and snowboarding. Discover more: www.emjreviews.com/emj-gold/new...

The remote prescription of the abortion pill #mifepristone is under threat from a lawsuit by Louisiana, but the Supreme Court has blocked the ruling for now. Discover the full story: www.emjreviews.com/emj-gold/new...

LEO Pharma has acquired Replay, a herpes simplex virus (HSV) gene therapy platform, for $50m. This will expand the company’s presence in rare dermatology. Learn more: hubs.ly/Q04f7NZs0 #dermatology #genetherapy #LEOPharma

The results are in 📣 It's time to see what held firm and what trends took shape. How did HCPs consume medical content in 2025? Find out now: www.emjreviews.com/emj-gold/inf... #pharmamarketing #medicalaffairs

Is the UK-US pricing deal working? New investments from #AstraZeneca and #BoehringerIngelheim suggest it is. The companies have pledged almost half a billion pounds to new sites in the country, indicating a thawing of frosty relations between the UK and pharma. www.emjreviews.com/emj-gold/new...

More exciting news: Well done to the #EMJPodcast for being shortlisted for the Audio Content of the Year at the 2026 Professional Publishers Association (PPA) Awards. Winners will be revealed on Wednesday 17 June 2026. Learn more: www.emjreviews.com/emj-gold/new...

Congratulations to @emjreviews.com for getting shortlisted in the Healthcare & Pharma category for The Drum Awards 2026 🏆 The awards recognise work that demonstrates effectiveness and innovation in healthcare communications. Read more: hubs.la/Q04dyFYl0

“Sometimes I don’t understand why people would want to do something else.” Andrew Menzies-Gow, VP, #AstraZeneca, loves his job. In this interview, he talks diagnosis gaps, shifting COPD thinking and fixing care. Read now: www.emjreviews.com/emj-gold/art... #Respiratory #COPD #asthma